| INTRODUCTION
Although influenza vaccines remain the most effective means to prevent seasonal influenza, they typically provide suboptimal protection in high risk groups. 1 In addition, vaccines may be completely ineffective in the event of an antigenic mismatch between viruses in the seasonal vaccine and those circulating in the community. 2, 3 In comparison, influenza antiviral drugs typically remain effective against antigenic drift variants or even newly emerged pandemic viruses as they target highly stable or conserved parts of the virus. In many countries, antiviral medication is administered to hospitalised patients with severe influenza illness and is stockpiled as part of pandemic preparedness plans. [4] [5] [6] Some countries, including Japan and the USA, also use substantial amounts of influenza antivirals for the treatment of uncomplicated influenza infection in otherwise healthy individuals. 7, 8 Compounds from only two classes of influenza antivirals are licensed for use in many countries. These are the adamantanes and neuraminidase inhibitors (NAIs). The adamantane compounds, amantadine and rimantadine, target the viral M2 protein required for virus uncoating during replication. 9 However, these compounds are no longer recommended for treatment of seasonal influenza A viruses due to widespread viral resistance. 10 NAIs impair the release of virus from infected host cells, and although the frequency of NAI resistance in currently circulating strains is low (<1%), 11 resistance to oseltamivir, the most widely used NAI, was widespread amongst former seasonal H1N1 viruses in 2008. 12, 13 More recently, localised clusters of oseltamivirresistant H1N1pdm09 viruses have been detected. 14, 15 Aside from concerns regarding resistance, the effectiveness of the NAIs is limited when delivered >48 hours after the onset of symptoms. Given these factors, there remains an important need for the development of influenza antiviral drugs that improve treatment effectiveness and can be delivered easily to patients with severe illness, remain effective when delivered late in the progression of disease and that have a low propensity for selecting for viral resistance. 
| HOST CELL TARGETING COMPOUNDS

| Nitazoxanide
NTZ is a compound of the thiazolide class of broad-spectrum antiviral drugs that is orally administered and rapidly deacetylated in the blood to the active metabolic form tizoxanide (TIZ). 16 NTZ was originally developed and licensed as an antiprotozoal/helminth drug and remains the only licensed treatment for Cryptosporidium infections. 17 In addition, NTZ/TIZ is also effective against a range of bacterial 18 and viral infections. 19 NTZ/TIZ was first identified to have the potential for antiviral properties during clinical trials for
Cryptosporidium treatment in patients with AIDS. 20 Since that time, NTZ/TIZ has been shown to inhibit various viruses including gastrointestinal viruses like rotavirus, and influenza viruses, hepatitis B and C viruses. 19 The mode of action of NTZ/TIZ against these viruses appears to differ. For rotavirus, TIZ interferes with the VP7 structural protein formation, while for hepatitis C, TIZ aids the activation of protein kinase R (PKR) resulting in downstream activation of the innate immune pathway. 19 For influenza, TIZ exerts its antiviral activity by interfering with the assembly of the viral haemagglutinin (HA).
21
TIZ inhibits influenza virus replication by impairing the trafficking of the HA from the endoplasmic reticulum (ER) to the Golgi, preventing the exit of mature virus particles from the host cell. 22 tract. An early concern regarding the removal of sialic acid from the respiratory epithelium was that it may increase the colonisation rate of Streptococcus pneumonia, but to the contrary, studies have indicated that it decreases the risk of secondary bacterial infections. 30 In vitro studies have shown that DAS181 treatment removed approximately 90% of sialic acid receptors on human airway epithelial (HAE) cells within 15 minutes and up to 15% of the dose was retained up to 7 days post-treatment. 31 At least 3 days was required for sialic acid receptor levels to return to normal. 31 As a broad-spectrum treatment of the respiratory epithelium, DAS181 has been shown to be active against a wide range of influenza viruses (H1N1pdm09, H3N2, H7N9, H5N1 and influenza B viruses), as well as parainfluenza viruses and human metapneumoviruses. [32] [33] [34] [35] For the treatment of highly pathogenic H5N1, DAS181 was found to be effective in vitro in human lung tissue cultures and in a mouse model where 1 mg/kg/day given prophylactically was found to protect against H5N1 infection, and 0.7 mg/kg/day reduced mortality by 94%. 36 Similar data were observed for the treatment of H7N9
| DAS181 (Fludase)
viruses, including an oseltamivir-resistant variant, where prophylactic administration of DAS181 completely protected mice from H7N9 infection, compared to untreated mice which died 9 days post-infection.
Treatment with 1 mg/kg/day DAS181 reduced viral lung titres significantly in both WT H7N9 and oseltamivir-resistant H7N9 infected mice, compared to placebo-treated controls. 37 Interestingly, a 48-hour delay in treatment still resulted in greater than 75% survival in H7N9 infected mice. Serial passage of influenza viruses in the presence of DAS181 selected for several mutations in the HA (G137R, S136T, S186I) and NA (W438L, L38P) which resulted in viruses with increased receptor binding, coupled with significantly reduced NA on the cell surface. 38 As a result, the replication fitness of the DAS181 selected viruses was compromised. 38 Four different formulations of DAS181, which differ in particle size, have been investigated in phase I and phase II trials. A phase II trial conducted over three influenza seasons examined the effectiveness of DAS181 F02 as a single 10 mg dose or 10 mg daily over 3 days. In mice receiving the multiple dose regimen, there was a significant decrease in viral shedding and viral load up to 5 days from the commencement of treatment. 39 The safety of 20 mg doses of DAS181 F03 and F04 delivered for up to 10 days was assessed in a phase I trial. The dose was well tolerated up to 7 days, but further dosing resulted in the onset of adverse respiratory events.
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DAS181 has also been tested in a small cohort of adults with wellcontrolled asthma. While the drug was associated with some adverse events such as chest discomfort, the drug was deemed safe for adults with uncomplicated asthma. 41 
| VIRAL POLYMERASE INHIBITORS
| T705 (favipiravir)
T705 (also known as favipiravir) is a substituted pyrazine derivative which inhibits the replication of a number of RNA viruses including influenza viruses. As a purine nucleoside analogue, T705 exerts its antiviral activity as a competitive substrate inhibitor of the RNAdependent RNA polymerase (RDRP) that is essential for the replication of RNA viruses. 42 Serial passage of viruses in increasing concentrations of T705 caused an increase in guanosine to adenine nucleotide mutations in the virus compared to viruses passaged in the absence of drug. 43 The increased mutation frequency, resulting in the generation of non-viable virus, is a key antiviral mechanism of T705. 43 This has also been described as the mechanism of action for the antiviral ribavirin. 44 T705 has broad-spectrum activity, also targeting and successfully inhibiting the RDRP of other viruses in vitro, and in many cases in vivo, such as West Nile virus, poliovirus and noroviruses. 45 In addition, T705 has also been shown to have some effectiveness against Ebola virus in small animal models 46, 47 
| JNJ63623872 (formerly known as VX-787)
JNJ63623872 (formerly known as VX-787) is a compound that inhibits the PB2 subunit of influenza A viruses by utilising host pre-mRNA as a primer for viral RNA synthesis during replication, a method known as "cap snatching". 56 The drug binds to key residues in the PB2 cap binding domain preventing the docking of the natural ligand, 7-methyl GTP, thereby preventing viral RNA synthesis. The drug exhibits strong antiviral activity in vitro against influenza A viruses including highly pathogenic avian influenza viruses and those that are resistant to the neuraminidase inhibitors, 46 but is ineffective against influenza B viruses due to the inherent differences in the structure of the PB2 caps. to JNJ6362387. 60 However, these PB2 substitutions are rarely observed in naturally occurring human isolates. 60 In patients undergoing JNJ63623872 treatment in a human challenge study, a M431I amino acid substitution in PB2 was selected in viruses in four of 72 patients.
These viruses showed a >50-fold reduction in JNJ63623872 susceptibility and had reduced viral fitness.
A placebo-controlled phase IIa study showed JNJ63623872 to be well tolerated and at the highest dose (1200 mg once daily for 5 days)
resulted in a 94% reduction in viral shedding compared to placebo. The JNJ63623872 treatment group had a quicker resolution of influenzalike symptoms (1.9 days) compared to the placebo group (3.7 days). 
| S-033188
S-033188 is a prodrug that is metabolised to an active form (known 
| MONOCLONAL ANTIBODIES
Several monoclonal antibodies (mAbs) are being developed as a treatment for severe influenza infection. Currently, five different mAbs which target the highly conserved stem region of the HA molecule of the virus and one targeted to the matrix protein are being evaluated in clinical trials. However, those summarised here are not an exhaustive list of all influenza mAbs in development. As the mAbs target conserved epitopes, they have the capacity to neutralise viruses across a broad range of influenza A subtypes. CR6261 is a mAb that binds to the helical region in the membrane-proximal stem of HA1/HA2, enabling the antibody to neutralise a broad spectrum of influenza A viruses. 63, 64 This mAb has also been shown to have beneficial prophylactic and therapeutic effects in ferrets infected with H5N1. 65 Another mAb targeted to membrane fusion is CR8020, which binds to HA stem epitopes, is active against group 2 HA subtypes of influenza A viruses and has been shown to neutralise H3N2 and H7N7
infections in vitro and in vivo. 66 CR8020 has been investigated in two placebo-controlled phase II trials in experimentally infected individuals (NCT01938352) as well as in hospitalised patients with influenza,
where it was also compared with the mAb CR6261 (NCT01992276).
However, it has been shown that CR8020 targets residues that are prone to antigenic drift and therefore if escape mutants arise, then effectiveness is likely to be reduced.
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MEDI8852 also targets the HA stalk, but has a greater potency and a broader spectrum of activity showing effective inhibition of all 16 influenza A HA subtypes. 68 MEDI8852 was shown to be superior to oseltamivir in preventing the death of mice and ferrets infected with H5N1 when treatment was administered up to 3 days post-infection.
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MEDI8852 was shown to be well tolerated in phase I clinical trials, 69 and patients are currently being recruited for a phase IIa study to evaluate its safety in patients with uncomplicated influenza (NCT02603952).
MHAA4549A is another HA stalk targeted mAb that is also effective at binding all influenza A subtypes. 70 Pre-clinical studies have shown efficacy in mice and ferrets challenged with H5N1 when treatment was delivered up to 72 hours post-infection. 71 Two phase I trials showed that the antibody was well tolerated as a single intravenous dose up to 10800 mg and had a mean half-life of 22.5-23.7 days. Another HA mAb, VIS-410, was effective at protecting mice from A(H7N9) virus challenge and improved viral clearance and spread in the lungs when delivered prophylactically. A single dose of 10 or 50 mg/kg protected all mice from death following infection with an oseltamivirresistant strain of influenza. 74 In a phase I trial, 2-50 mg/kg doses of VIS-410 were found to be safe and well tolerated by the cohort.
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TCN032 differs from those previously discussed as it targets an epitope at the N-terminus of the matrix 2 protein which is a conserved epitope in influenza A viruses. Binding to this target has been shown to inhibit almost all influenza virus types and protected mice from lethal challenges with either H5N1 or H1N1 influenza viruses. 76 In a phase IIa human challenge study (NCT01719874), a single dose of TCN032 was found to be well tolerated. 77 
| CONCLUSION
There is currently an unmet need for better influenza antiviral drugs showing substantially improved effectiveness compared to currently available drugs when treatment is initiated >48 hours after symptom onset. In addition, the propensity for the selection of viral resistance to
these new compounds appears to be lower than that seen for the NAIs or adamantanes. Finally, some of the new antivirals have activity against a number of different respiratory viruses which could mean that these broad-spectrum compounds may be prescribed for a respiratory disease without the need for a specific laboratory confirmed diagnosis.
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